United States: CMS Proposes Fundamental Reimbursement Methodological Change For 340B Drugs Used In Hospital Outpatient Setting

Last Updated: August 4 2017
Article by Thomas Barker

We have noted before the link between the Medicaid prescription drug rebate program and the 340B program. As a refresher, in order to have its outpatient drugs covered by Medicaid, the manufacturer must agree to three separate requirements. First, the manufacturer must agree to provide a rebate to Medicaid equal to the greater of 23.1% of the average manufacturer price (AMP) of the drug, or AMP minus the best price of the drug. This first requirement ensures that Medicaid is getting, with some exceptions, the lowest price offered to any purchaser for the drug.

Second, the manufacturer must agree to sell the drug via the Federal Supply Schedule to the Department of Veterans Affairs, the Department of Defense, the Coast Guard, and public health service agencies such as the Indian Health Service. This second requirement ensures that these agencies also get a significant discount off of the AMP for the drug – one that typically exceeds the Medicaid discount.

Third, the manufacturer must agree to participate in the 340B program. This program – named after its statutory location in the Public Health Service Act – permits certain "covered entities" to purchase a covered outpatient drug at the Medicaid price (or, if the covered entity participates in the "prime vendor program", at an amount even lower than the Medicaid price). Covered entities include organizations such as community health centers and heavily disproportionate share acute care hospitals. In addition, the Affordable Care Act (ACA) added to the list of covered entities cancer hospitals, pediatric hospitals, critical access hospitals, sole community hospitals, and rural referral centers. The "link" between the 340B program and Medicaid is this: if a manufacturer refuses to make 340B prices available to covered entities, it cannot have its drugs covered under Medicaid (or Medicare Part B in the case of separately payable physician administered drugs).

The 340B program is administered by the Health Resources and Services Agency (HRSA), a sister agency of the Centers for Medicare & Medicaid Services (CMS) within the Department of Health and Human Services (HHS). The 340B program is administered mainly through program guidance; the statute gives HRSA very limited authority to issue regulations to implement the program. In fact, a federal court decision from 2014 struck down an attempt by HRSA to regulate in one particular area of the program. See PhRMA v. HHS, 43 F. Supp. 3d 28 (D.D.C. 2014).

Earlier this month, CMS proposed a major change in Medicare reimbursement policy when 340B hospitals purchase drugs under the 340B program for use in an outpatient setting. This policy change will surely be vehemently opposed by hospitals. CMS believes, however, that it has strong empirical support – through the Medicare Payment Advisory Commission (MedPAC), the HHS Office of Inspector General, and the Government Accountability Office, among other organizations – for the policy change. Recently, Congress has also enhanced its scrutiny regarding oversight of the 340B program, including its relationship with Medicare Part B.

Under current law, outpatient services under the Medicare program are reimbursed under the hospital outpatient prospective payment system, or HOPPS. Most drugs used in outpatient procedures are reimbursed separately from the HOPPS amount and are paid at an amount equal to the average sales price (ASP) for the drug, plus 6%. For example, if the ASP for a cancer drug is $2,000 per dose, the hospital receives a payment of $2,120 ($2,000 + (.06)*( $2,000)) for the drug. Because hospital outpatient services are a Part B benefit under Medicare, the Medicare beneficiary faces a copayment of 20% for the service – so in this example, a copayment of $424, while Medicare pays the remaining $1,696.

If the hospital using the cancer drug is a 340B covered entity, however, it likely paid far less than the ASP of $2,000 for the drug. A MedPAC study from 2015 noted that 340B hospitals received a minimum discount of 22.5% for 340B drugs, and also noted that the discount is likely significantly higher. Using the MedPAC-estimated discount for illustrative purposes, the hospital would have paid $1,550 for the cancer drug in the above example, but would receive $2,120 from a combination of Medicare payments and beneficiary cost sharing, for a profit of $570. It is this excess payment – $570, in the cancer drug example – that CMS has targeted in the proposed hospital outpatient rule.

Under the CMS proposal, a 340B covered entity that is a hospital would no longer be paid ASP plus 6% for most outpatient drugs. Rather, the 340B hospital would be paid at a rate of ASP minus 22.5% for most separately payable outpatient drugs paid under HOPPS. CMS states that the proposed reasons for the rule are, first, to better match payment and acquisition costs of the drug. Second, the policy is designed to reduce spending by Medicare beneficiaries (in terms of lower cost sharing) and the Medicare program overall. As such, the proposal can be seen as part of the Trump Administration's initiatives to lower prescription drug spending.

Under the proposed rule, CMS would assume that the hospital billing for the drug is a 340B covered entity; hospitals that are not would need to enter a modifier on the claim for the service indicating that it is entitled to the higher (ASP+6%) payment. CMS intends to provide further details on the modifier when it finalizes the HOPPS rule, but the agency stated the modifier would become effective beginning January 1, 2018. CMS also intends to address billing for drugs dispensed to dual-eligible beneficiaries, as drugs dispensed to Medicaid beneficiaries do not qualify for 340B pricing.

CMS would exclude from its policy covered outpatient drugs that are subject to the OPPS new drug pass-through, on the grounds that the statute mandates a specific payment rate for those drugs. In addition, the policy would not apply to vaccines. The agency also solicits comments on whether other types of products, such as blood clotting factors, should be excluded. And although the agency does not address it in the proposed rule, CMS will likely receive comments urging the agency to not apply the policy to orphan drugs, at least when billed under HOPPS by the ACA-expanded list of covered entities, on the theory that those entities cannot, by statute, receive 340B pricing on orphan drugs.

The proposal is likely to achieve significant savings if implemented as proposed. CMS is soliciting comments on whether to use those savings to either increase payments under the HOPPS generally, or else apply the savings across the board by increasing the HOPPS conversion factor.

Overall, the CMS proposal is a fundamental change in policy that is likely to be strenuously opposed by hospitals. Although pharmaceutical and biological manufacturers have criticized the growth in the 340B program over the past ten years, the proposed change does not benefit manufacturers, so it is not clear how aggressively they will support the provisions in the proposed rule. It is likely that manufacturers believe that additional reforms to the 340B program are necessary. On that point, manufacturers and covered entities likely agree.

To view Foley Hoag's Medicaid and the Law blog please click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
25 Oct 2017, Webinar, Boston, United States

Foley Hoag will present a 60-minute webinar on Wednesday, October 25 at 12:30 pm EDT, offering guidance for in-house counsel regarding the basics of trademark and design protection in the European Union. Attendees will learn about the opportunities and pitfalls to be on the lookout for when looking to secure, protect, and enforce an IP portfolio overseas.

1 Nov 2017, Webinar, Boston, United States

Please join Foley Hoag on Wednesday, November 1, 2017 for a webinar that covers the details of drafting an appropriate arbitration clause for your company’s commercial contracts.

9 Nov 2017, Conference, Waltham, United States

Please join us on Thursday, November 9 at the Westin Waltham Hotel for our quarterly New England M&A Forum, which brings the latest in market trends and recent legal developments to the New England M&A professionals' community.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.